ANI Pharmaceuticals has launched Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. The company's Carbamazepine Extended-Release Capsules are the generic version of the Reference Listed Drug (RLD) Carbatrol.

"Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us,” stated Nikhil Lalwani, President and Chief Executive Officer, ANI. “The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines while maintaining the highest standards of quality and compliance.”

The US annual sales for Carbamazepine Extended-Release Capsules total approximately USD 65 million, based on February 2026 Moving Annual Total (MAT) IQVIA data.